Clearside Biomedical’s Phase IIb ODYSSEY study of its drug-device combination CLS-AX (axitinib injectable suspension) has ...

The global AMD drugs market is set to grow from USD 10.46 billion in 2024 to USD 17.37 billion by 2029, reflecting a robust ...

Age-related macular degeneration (AMD) is a leading cause of vision loss for adults over 50 in the United States. According ...

Clearside Biomedical today announced that the ODYSSEY study of its drug-device combination achieved its primary and secondary ...

SOL-1 is now expected to be enrolled and fully randomized by year-end 2024Topline clinical data from SOL-1 are now expected in Q4 2025BEDFORD, ...

For wet AMD, the goal of this treatment is to slow ... Anti-VEGF injections contain medications that treat abnormal and leaky blood vessels in your retina. The procedure is performed by a type ...

Ocular Therapeutix's Elutyx drug delivery platform offers sustained long-term effects. See why OCUL stock is a Buy.

D stock is a contrarian trade opportunity based on the market assumption that the promising Wet Amd eye disease gene therapy ...

Megan Baldwin, PhD, MAICD, to retire from the Board and has chosen not to stand for re-electionAs Founder and Chief Innovation Officer, Dr.

Nvidia and AMD make the best graphics cards you can buy, but choosing between them isn’t easy. Unlike previous generations, AMD and Nvidia trade blows point-for-point in 2024, and picking a ...

Clearside Biomedical's CLS-AX Phase 2b trial for wet AMD met primary and secondary endpoints, showing stable vision and ...

A decade into reformulating Pfizer’s oral renal cell carcinoma drug Inlyta (axitinib) into a treatment that can be injected ...